Orphan Drug Companies Warned To Beware Of The Dutch Lock System
Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.
You may also be interested in...
Gilead’s breast cancer drug Trodelvy is too expensive for the benefits it offers and will not be reimbursed in the Netherlands unless the company drops its price, said the Dutch health minister.
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.
The IGBA has welcomed Mexican pharmaceutical industry association ANAFAM as an associate member.